Form 4: Twist Bioscience Executive Sells Shares for Tax Obligations

Dennis Cho, SVP and Chief Legal Officer of Twist Bioscience, sold 230 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a transaction on a Form 4 filing.
• On June 20, 2025, Mr. Cho disposed of 230 shares of TWST common stock.
• The shares were sold at a price of $35.755 per share.
• This sale was a 'sell to cover' transaction, mandated by the issuer to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs), and was explicitly stated not to be a discretionary trade by Mr. Cho.
• Following this transaction, Mr. Cho beneficially owns 104,737 shares of Twist Bioscience common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax purposes, not indicative of discretionary selling or a change in sentiment, thus it is neutral.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• "Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person."

Industry Context

This transaction is a routine 'sell to cover' event, common across all industries for executives who receive equity compensation. It is a standard mechanism to satisfy tax liabilities arising from the vesting of Restricted Stock Units (RSUs) and does not typically reflect a change in the executive's outlook on the company or broader industry trends.

Comparison to Industry Standards

• The 'sell to cover' transaction is a widely accepted and common practice for executives across various industries to manage tax obligations associated with equity compensation, such as RSU vesting.
• This type of non-discretionary sale is standard and does not typically signal a lack of confidence in the company, unlike discretionary open-market sales.
• No specific comparable companies, projects, or results are relevant for this type of routine tax-related insider transaction.

Stakeholder Impact

• Shareholders: The transaction is a routine tax-related sale and is unlikely to have a significant impact on shareholder perception or the company's valuation.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Key Dates

Recommendation

Keywords

Twist Bioscience, TWST, SEC Form 4, insider transaction, stock sale, Restricted Stock Units, RSU, tax withholding, executive compensation, Dennis Cho